Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark

a routine clinical care prescription study

Jakob S. Knudsen*, Reimar W. Thomsen, Anton Pottegård, Filip K. Knop, Henrik T. Sørensen

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.

OriginalsprogEngelsk
TidsskriftJournal of Diabetes
Vol/bind11
Udgave nummer8
Sider (fra-til)690-694
ISSN1753-0393
DOI
StatusUdgivet - 1. aug. 2019

Fingeraftryk

Drug Utilization
Denmark
Prescriptions
Drug Combinations
Diabetes Complications
Marketing
Comorbidity
Liraglutide
Population

Emneord

  • cross-sectional studies
  • diabetes pharmacology
  • drug utilization
  • glucagon-like peptide-1 receptor
  • liraglutide

Citer dette

@article{5f1c731858be4bda8e44944099e00b08,
title = "Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study",
abstract = "Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57{\%}) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73{\%} of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.",
keywords = "cross-sectional studies, diabetes pharmacology, drug utilization, glucagon-like peptide-1 receptor, liraglutide, cross-sectional studies, diabetes pharmacology, drug utilization, glucagon-like peptide-1 receptor, liraglutide",
author = "Knudsen, {Jakob S.} and Thomsen, {Reimar W.} and Anton Potteg{\aa}rd and Knop, {Filip K.} and S{\o}rensen, {Henrik T.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1111/1753-0407.12919",
language = "English",
volume = "11",
pages = "690--694",
journal = "Journal of Diabetes",
issn = "1753-0393",
publisher = "Wiley-Blackwell",
number = "8",

}

Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark : a routine clinical care prescription study. / Knudsen, Jakob S.; Thomsen, Reimar W.; Pottegård, Anton; Knop, Filip K.; Sørensen, Henrik T.

I: Journal of Diabetes, Bind 11, Nr. 8, 01.08.2019, s. 690-694.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark

T2 - a routine clinical care prescription study

AU - Knudsen, Jakob S.

AU - Thomsen, Reimar W.

AU - Pottegård, Anton

AU - Knop, Filip K.

AU - Sørensen, Henrik T.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.

AB - Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.

KW - cross-sectional studies

KW - diabetes pharmacology

KW - drug utilization

KW - glucagon-like peptide-1 receptor

KW - liraglutide

KW - cross-sectional studies

KW - diabetes pharmacology

KW - drug utilization

KW - glucagon-like peptide-1 receptor

KW - liraglutide

U2 - 10.1111/1753-0407.12919

DO - 10.1111/1753-0407.12919

M3 - Journal article

VL - 11

SP - 690

EP - 694

JO - Journal of Diabetes

JF - Journal of Diabetes

SN - 1753-0393

IS - 8

ER -